8-K: Aclarion Secures $10.4M, Extends Cash Runway to 2028

Aclarion, Inc. announced the closing of a $10.4 million common stock financing, strengthening its balance sheet and extending its cash runway into 2028.

Summary

• Aclarion, Inc. successfully closed a $10.4 million common-stock-only financing at a price of $5.18 per share.
• The transaction involved the sale of 200,000 shares of common stock and pre-funded warrants to purchase up to 1,800,000 shares of common stock.
• As a result of this financing, Aclarion's cash reserves increased to $21.6 million as of January 12, 2026, and the company now operates with zero debt.
• The company's cash runway has been significantly extended into 2028, based on current operating plans.
• This strengthened capital position is expected to fully support continued execution across commercialization, evidence generation, and strategic partnerships for its Nociscan technology.

Sentiment

Score: 8

Explanation: The filing reports a successful capital raise that significantly improves the company's financial position, eliminates debt, and extends its operational runway. This provides a strong foundation for executing strategic initiatives and de-risks future milestones, indicating a very positive outlook from a financial stability perspective.

Positives

• Successfully completed a $10.4 million common-stock-only financing, described as a 'clean capital raise structure'.
• Significantly strengthened the balance sheet, with cash reserves reaching $21.6 million as of January 12, 2026.
• Achieved a debt-free balance sheet, enhancing financial stability.
• Extended the company's cash runway into 2028, providing substantial operational longevity and de-risking future milestones.
• Preserved capital structure integrity, which is crucial for long-term value creation.
• Enhanced strategic flexibility as the Nociscan product continues to gain clinical and commercial traction.

Risks

• Uncertainties and risks could significantly affect current plans, expectations, and future results of operations and financial condition.
• Risks related to the enrollment of patients in the ongoing CLARITY clinical trial.
• Risks concerning the expected date of internal interim results from clinical trials.
• Risks associated with the potential benefits and adoption of Nociscan technology.
• Risks related to future regulatory and commercialization activities.
• The cash runway extension into 2028 is based on current operating plans, which are subject to change and may not accurately reflect future cash needs.
• General risks and uncertainties are discussed more fully in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and other subsequent SEC filings.

Future Outlook

The company anticipates accelerating enrollment in its CLARITY trial, aiming for 25% patient enrollment by the end of Q2 2026, with an initial internal readout after the first cohort completes their 3-month follow-up. Aclarion also plans to complete and publish multiple real-world evidence trials, expand MRI manufacturer access to grow the global market by over 30%, launch Nociscan software version 2.8 in Q1, and actively collaborate with commercial payers for broad reimbursement coverage. The financing is expected to support these initiatives and extend the cash runway into 2028.

Management Comments

• "We have transformed Aclarion's balance sheet over the past year and positioned the Company for long-term value creation with a pristine capital structure." Brent Ness, Chief Executive Officer of Aclarion.
• "This financing clearly de-risks our ability to reach significant milestones within the timeline of our cash runway." Brent Ness, Chief Executive Officer of Aclarion.
• "With a debt-free balance sheet, strong cash reserves, and extended cash runway into 2028, we are focused squarely on execution, expanding adoption of Nociscan, deepening clinical evidence, and building strategic relationships that drive durable growth for patients, providers, payers, and shareholders." Brent Ness, Chief Executive Officer of Aclarion.

Industry Context

Aclarion operates in the healthcare technology sector, specifically targeting chronic low back pain with its Nociscan platform, which leverages Magnetic Resonance Spectroscopy (MRS) and augmented intelligence (AI) algorithms. This financing strengthens its position to compete in the diagnostic imaging and pain management markets, where innovation in non-invasive, evidence-supported tools is crucial for improving patient outcomes and securing payer coverage. The focus on expanding MRI manufacturer access and collaborating with commercial payers indicates a strategic approach to integrate Nociscan more broadly into existing healthcare infrastructure and reimbursement pathways, a common challenge for novel medical technologies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The financing strengthens the company's financial position and extends its cash runway, potentially reducing the risk of near-term dilution and supporting long-term value creation. However, the offering itself involves dilution from the issuance of new shares and warrants.
• Employees: Enhanced financial stability provides greater job security and resources for continued operations and growth.
• Customers (Physicians/Patients): Extended runway and focus on execution should lead to continued development and broader adoption of Nociscan, potentially improving access to the technology for chronic low back pain diagnosis.
• Suppliers/Partners: Improved financial health makes Aclarion a more reliable partner.
• Creditors: The company is now debt-free, significantly reducing credit risk.

Next Steps

• Accelerate enrollment in the CLARITY trial, aiming for approximately 25% patient enrollment by the end of Q2 2026.
• Internally review initial readout from the CLARITY trial after the first cohort completes their 3-month follow-up visit.
• Complete and publish multiple investigator-initiated real-world evidence trials.
• Expand major MRI manufacturer access, with a goal of growing the available global market size by greater than 30%.
• Support broader clinician education and awareness initiatives through accelerated participation at societal-sponsored CME events.
• Launch version 2.8 of the Nociscan software in Q1.
• Actively collaborate with multiple commercial payers in the US market to evaluate broad reimbursement coverage of Nociscan.

Key Dates

Recommendation

The successful completion of a $10.4 million financing, resulting in a debt-free balance sheet with $21.6 million in cash and an extended cash runway into 2028, significantly de-risks Aclarion's operational and strategic execution. This strong financial position provides ample resources to advance key initiatives like the CLARITY trial, Nociscan software development, market expansion, and payer collaborations. The 'clean capital raise structure' also suggests minimal adverse impact on existing capital structure integrity. This substantial improvement in financial health, coupled with clear strategic objectives for a promising healthcare technology, presents a compelling investment opportunity for long-term value creation.

Keywords

Aclarion, ACON, Nociscan, Healthcare Technology, Medical Devices, Chronic Pain, Low Back Pain, MRS, AI, Financing, Capital Raise, Balance Sheet, Cash Runway, Clinical Trials, CLARITY trial, Nasdaq